{"id":69,"date":"2015-08-27T16:33:34","date_gmt":"2015-08-27T16:33:34","guid":{"rendered":"http:\/\/deskiziarecords.com\/CIFASD\/?page_id=69"},"modified":"2024-06-07T01:25:07","modified_gmt":"2024-06-07T01:25:07","slug":"research","status":"publish","type":"page","link":"https:\/\/cifasd.org\/research\/","title":{"rendered":"RESEARCH"},"content":{"rendered":"[vc_row][vc_column width=”1\/1″][vc_column_text disable_pattern=”true” align=”left” margin_bottom=”0″]\n
<\/p\/>\n
Administrative Resource of the CIFASD<\/strong> U24 AA014811<\/span> | San Diego State University<\/p>\n The Collaborative Initiative on Fetal Alcohol Spectrum Disorders (CIFASD) is a multidisciplinary, international consortium of research projects and resources charged with improving prevention, diagnosis, and treatment of FASD. The Administrative Core\/Resource (AdminC) of CIFASD has led this consortium since it was first established in 2003 and plays a critical leadership role in coordinating research efforts and ensuring progress toward consortium goals. CIFASD consists of multiple collaborative components including three resource U24s (AdminC, Diagnostic-Telemedicine, and Data Coordination), eight clinical and\/or translational U01 projects, and two exploratory UH2 projects. One goal of CIFASD is to improve identification of individuals affected by prenatal alcohol exposure (PAE). This will be accomplished by assessing biomarkers of exposure or effects, such as immune, HPA, and miRNA profiles. In addition, CIFASD is implementing novel tools, such as 3D facial and neurobehavioral screening to improve identification of FASD remotely through eHealth, providing more universal accessibility. A focus on telemedicine provides access to dysmorphology evaluations in more diverse and remote populations. CIFASD continues to study the effects of PAE on the whole body across the lifespan. Previous results from CIFASD suggest that PAE may be a risk factor for numerous health issues (e.g., hypertension and diabetes). By using interrelated clinical and preclinical research approaches, health outcomes and markers will be examined at several ages. CIFASD continues work on interventions to mitigate the damaging effects of PAE including a trial on tDCS, and expansions of eHealth initiatives to provide interventions to assist affected individuals and their families. To improve prevention of maternal alcohol consumption and reduce risk for FASD, a hybrid prevention strategy will be investigated. Implementation is a new focus of CIFASD; as unless tools created in CIFASD are utilized clinically, their potential won\u2019t be fully realized. Collectively, CIFASD projects will move the FASD field forward, improving prevention, diagnosis, and treatment and with the technology available in eHealth serve a wide population. The Specific Aims of the AdminC are: 1) Provide scientific and administrative direction, leadership, and oversight; 2) Facilitate communication among the projects and result dissemination; 3) Assist with data management; 4) Provide annual progress evaluations, and 5) Support projects by providing outreach, eHealth, and implementation science resources and services. The AdminC supports the interactive framework of CIFASD by regular communications with all members through monthly and biannual meetings; leading the Steering Committee in the establishment and implementation of CIFASD priorities and policies; supporting the Science Advisory Board\u2019s evaluations of progress on each component and the overall mission of CIFASD; serving as the liaison between the consortium\u2019s project scientists and its NIAAA advisors; and supporting outreach, eHealth, and implementation efforts.<\/p>\n The consequences resulting from prenatal alcohol exposure are wide-ranging and a major and costly public health problem. The goal of the CIFASD consortium is to enhance the identification and treatment of FASD utilizing a multidisciplinary approach consisting of both basic science and clinical research. The collaborations among research projects will allow CIFASD to improve the diagnosis and treatment of FASD, moving the field forward in ways that could not be easily achieved by individual projects.<\/p>\n FASD Diagnostic Telemedicine Resource<\/strong> U24 AA014815 <\/span> | University of California, San Diego<\/p>\n Prenatal alcohol exposure is estimated to impact 1-5% of children in the US alone. Yet, many individuals who have been exposed prenatally to alcohol and suffer from fetal alcohol spectrum disorders (FASD) fail to be recognized. This failure is due, in large part, to a paucity of specialized clinics and expert dysmorphologists who are trained to identify FASD. Access to appropriate diagnostic expertise is particularly limited in remote areas. Unfortunately, if individuals with FASD are not recognized and diagnosed, they do not receive critically needed services nor can they access potential interventions early in life, when intervention is most likely to be effective. The CIFASD5 Diagnostic-Telemedicine Resource (DTR) will ensure consistent and accurate assessment of the physical characteristics of FASD across the CIFASD research sites. In addition, the DTR will address the critical need for increased diagnostic capacity through training of non-expert practitioners across CIFASD5 sites using telemedicine-based methods. In the previous CIFASD4 iteration, telemedicine approaches were tested for this purpose in a small sample of clinicians and found to be an effective method for training and monitoring of new examiners. In CIFASD5, this method will be extended to multiple sites and be employed in the evaluation of over 1,800 children and adults. However, telemedicine alone is insufficient to expand capacity and ensure consistency and accuracy of diagnosis. To that end, several novel eHealth tools have been developed to assist in the detection of physical features associated with prenatal alcohol exposure. These tools hold promise in providing simple and efficient ways to screen and identify FASD. These include MorpheusQ, a smart-phone based app that automates facial feature detection; Face-to-Gene, a 2D facial image diagnostic aid used by clinical geneticists to screen for potential syndromes; and 3D facial image signatures. These tools are scalable and have the potential to improve screening and diagnosis across the globe, even in remote areas, such as in Alaska. However, the diagnostic accuracy of these tools needs to be systematically compared to standardized dysmorphological exams. It is essential to determine whether eHealth tools can effectively replace and\/or improve traditional exams before they are widely implemented.<\/p>\n The primary goal of the CIFASD Consortium Diagnostic-Telemedicine Resource is to ensure consistent and accurate diagnoses of children and adults with fetal alcohol spectrum disorders (FASD) at study sites throughout the world. Because there is a critical shortage of health care practitioners who have the expertise to make this diagnosis, the Diagnostic-Telemedicine Resource will train new practitioners using telemedicine, aided by novel eHealth tools to perform these examinations. Finally, we will test these methods in delivering diagnostic services for FASD to remote areas of Alaska.<\/p>\n CIFASD Data Coordination Resource<\/strong> U24 AA030169<\/span> | Indiana University – Purdue University at Indianapolis<\/p>\n Almost 10% of pregnancies world-wide were reported to have prenatal alcohol exposure (PAE) (Popova, Lange, Probst, Gmel, & Rehm, 2017). In the United States a conservative estimate of Fetal Alcohol Spectrum Disorders (FASD) in first-grade children was 1-5% (May et al., 2018). These numbers are expected to increase, given the slight but steady rise in alcohol use among pregnant women (Denny, Acero, Terplan, & Kim, 2020). NIAAA established the Collaborative Initiative on the Fetal Alcohol Spectrum Disorders (CIFASD) to inform and develop effective interventions and treatment approaches for FASD through a highly integrated, multidisciplinary research program involving basic scientists and clinical investigators. Central to the success of CIFASD is strong central coordination provided through the Administrative Resource and a Data Coordination Resource (DCR). As part of CIFASD5, the DCR will collaborate with all projects and resources within the consortium to provide support and management with respect to data collection, storage and sharing. Based on this central role, the DCR will coordinate the efforts of the CIFASD5 investigators conducting human subjects research to meet the requirement of depositing data into the NIAAA Data Archive (NDA) and will serve as the primary contact with NDA in the biannual transfer of data to the NDA. The DCR will be responsible for ensuring data sharing in CIFASD5 conforms with NIH Policy. In addition, the DCR will support the efforts of the Administrative Resource in tracking progress of CIFASD5. To meet these goals, the DCR proposes the following specific aims: 1. Create a Data Coordination Resource (DCR) database for CIFASD5. 2. Serve as the CIFASD5 point of contact for the NIAAA Data Archive. 3. Expand the functionality of the DCR database. 4. Support the distribution of archived CIFASD data. 5. Maintain an online registry of consented CIFASD research participants available for recruitment into other projects.<\/p>\n The Data Coordination Resource will create an integrated database consisting of a vast array of data collected from the CIFASD projects in an effort to accurately recognize those with prenatal alcohol exposure (PAE), improve interventions to mitigate the effects of PAE, better understand the effects of PAE across the lifespan, and to reduce the incidence of PAE. These data will be shared with the broader research community, contributing to further understanding the effects of PAE and enhance future clinical and translational research.<\/p>\n Cardiovascular Disease in Fetal Alcohol Spectrum Disorder<\/strong> U01 AA030185<\/span> | Boston Children\u2019s Hospital<\/p>\n The incidence of congenital heart defects (CHDs) and cardiovascular disease (CVD) in patients with fetal alcohol spectrum disorder (FASD) are poorly characterized. Cardiovascular abnormalities may be common in FASD; however, comprehensive retrospective studies on lifetime CVD risk in adult patient cohorts have yet to be performed. Cellular and molecular mechanisms underlying FASD-mediated CHD and CVD are also largely unknown along with any biomarkers that would allow the patient population to be stratified based on CVD risk. Here we present preliminary data from our retrospective clinic cohort that demonstrate that females with FASD have an overall increase in CHD, myocardial infarction (MI) rate, and the likelihood of being diagnosed with any CVD in adulthood. Females with FASD also have significantly reduced ejection fraction relative to matched controls. These data suggest that FASD is a risk factor for CHD in newborns and CVD in adults. In a zebrafish model of embryonic alcohol exposure (EAE), we confirmed a primary defect in cardiomyocyte migration that causes subsequent functional and structural heart abnormalities, including contractility deficits and ventricular wall abnormalities that persist through adulthood. Our findings indicate that EAE zebrafish can serve as a model for lifelong cardiac function in the presence and absence of CHD. We propose three Specific Aims to test the central hypothesis that FASD patients have an increased incidence of CVD and that the zebrafish EAE model will uncover novel molecular mediators and biomarkers that explain and predict CVD risk. In Specific Aim 1, we will perform a retrospective study to determine CVD incidence in an adult FASD patient cohort, including CHD, hypertension, cardiomyopathy, MI, cerebrovascular accident, and embolism, as well as their association with other metabolic and inflammatory conditions. In Specific Aim 2, we will define molecular mechanisms underlying embryonic heart defects in a zebrafish EAE model by identifying and functionally evaluating the impact of molecular alterations in migratory myl7+ cardiomyocytes that form the cardiac cone through hypothesis-driven (PDGF pathway) and unbiased (bulk RNA-sequencing on FACS-isolated myl7+ cardiomyocytes) approaches. In Specific Aim 3, we will test the hypothesis that EAE adults with a CHD are susceptible to cardiac dysfunction and cardiomyopathy due to lasting alterations in cardiac structure, function, and molecular signature. Taken together, the proposed studies will provide fundamental insights into the cardiovascular health outcomes of patients with FASD, reveal novel molecular mediators of EtOH-induced CHDs, and identify biomarkers of adult cardiac dysfunction in EAE adults. Cardiovascular diseases may contribute significantly to morbidity and mortality in affected patients. By identifying which CVD outcomes impact FASD patients and what additional metabolic and inflammatory factors indicate risk, we will provide an opportunity for early intervention. Further, identification of molecular mediators of CHD and cardiomyopathy in a zebrafish model of EAE will allow us to expand our mechanistic understanding of the effects of PAE across the lifespan.<\/p>\n The long-term goal of this research is to decipher cardiovascular health outcomes in adults with FASD and to identify novel molecular mechanisms and biomarkers for ethanol-induced congenital heart defects and subsequent cardiac dysfunction in adulthood. We propose to accomplish these goals through a retrospective study on adult patients with and without FASD and by evaluation of a zebrafish model of embryonic alcohol exposure. Our findings will enable early identification or intervention in at-risk patients with FASD and expand our mechanistic understanding of the lasting effects of prenatal alcohol exposure on the heart.<\/p>\n Whole body Effects of PAE across the Life Span: Early Markers of & Clinical Interventions for Children and Adolescents in Ukraine<\/strong> U01 AA014835 <\/span> | University of California, San Diego<\/p>\n Numerous comorbidities have been identified as relatively common among children and adolescents with prenatal alcohol exposure (PAE) or fetal alcohol spectrum disorders (FASDs) including sleep disturbances, hypertension, abnormal eating behaviors, altered growth patterns, and comorbid depression and anxiety. In addition, emerging data suggest that several adult diseases of developmental origin, such as diabetes, atherosclerosis, cardiovascular and autoimmune disorders are over-represented and have earlier age at onset in adults with FASDs. It is imperative to better understand the prevalence and co-occurrence of these disorders as early as possible in the life course of children and adolescents with PAE, ideally at the sub-clinical stage, in order to intervene in clinically meaningful ways. Building on the existing Collaborative Initiative on Fetal Alcohol Spectrum Disorders (CIFASD) longitudinal cohort study in Ukraine, we aim to fill this critical gap in knowledge in two ways. First, we will compare the prevalence and characteristics of subclinical and clinical signs\/symptoms of current and developing metabolic and other chronic diseases and contributing factors in 180 children\/adolescents with PAE age-matched to 120 children\/adolescents with no\/minimal PAE. This includes comparing prevalence of premorbid or comorbid hypertension, hyperlipidemia, impaired glucose tolerance\/insulin resistance, and cardiovascular disease and also comparing growth parameters, physical activity, dietary intake, adverse childhood experiences, sleep disturbances, and measures of anxiety and depression. Second, we will compare findings on a panel of experimental measures of structure or function that can help illuminate mechanisms of PAE-related comorbidities across the lifespan in the same cohort of 300 children and adolescents. Experimental measures include capillary microvasculature, telomere length, and patterns of miRNA expression. Findings that are actionable will translate on the individual level to clinical guidance provided to the participant and caregiver. Furthermore, in keeping with one of the primary goals of CIFASD5, findings of this study will directly inform future intervention targets in children and adolescents to help remediate, ameliorate or prevent progression of pre-clinical or clinical conditions identified in the study evaluations. We will also work collaboratively with other investigators in the CIFASD Consortium to interactively address the overall goals of the Consortium in improving diagnosis and treatment of FASD.<\/p>\n A better understanding of the prevalence and co-occurrence of relatively common comorbidities among children and adolescents with prenatal alcohol exposure (PAE) is essential in order to intervene in clinically meaningful ways. These complex comorbid conditions are often the most challenging, disruptive, and costly health issues that families with a child affected by alcohol must cope. This study will document the prevalence and co- occurrence of early-stage indicators of possible or probable future chronic disease in children\/adolescents with PAE.<\/p>\n A Multisite Study of Prenatal Alcohol Exposure: Effects of Inflammation and Endocrine Dysfunction in Adulthood<\/strong> U01 AA026108<\/span> | Emory University and University of Vancouver<\/p>\n Although the impact of prenatal alcohol exposure (PAE) on early development has been well established, the Developmental Origins of Health and Disease (DOHaD) hypothesis suggests there may be longer- term consequences that increase the risk for adult diseases or disorders. Previously, it has been difficult to isolate the effects of PAE from those associated with other life experiences in affected individuals so that, often, the role of PAE may be overlooked. In fact, viewed from this context, PAE may be considered the first in a series of adverse exposures that result, eventually, in a higher risk for negative outcomes in this vulnerable population. Programing of fetal systems by PAE may alter the developmental trajectory and result in a sensitized organism that is vulnerable to later life challenges. The endocrine and immune systems have been found to be highly susceptible to programming by early life events, and together are thought to play key roles in linking early life adverse exposures with long-term health and functional outcomes. Thus, programming of these systems may be one mechanism by which PAE impacts adult health and neurobehavioral outcomes. In our ongoing CIFASD4 research negative impacts of PAE on physical and mental health outcomes in midlife were observed and attributable to both PAE and to associated early life adversity and social factors. Also noted were long-lasting, adverse changes in immune function, with inflammation starting in infancy and lasting into adulthood, suggesting an increased inflammatory burden over the life course. In the proposed study, we will test a \u201cmultiple hit\u201d hypothesis that PAE results in a vulnerable organism that may be further impacted by social adversity and lack of resources\/coping skills, resulting in immune and endocrine dysregulation that in turn, may be key drivers of early-onset health and neurobehavioral problems over the life course. 360 individuals representing a diverse sample of affected individuals from three sites, Atlanta, Seattle, and Canada, will participate in a quasi-experimental study of PAE effects in midlife. In addition to measuring PAE\/FASD and environmental conditions, we will use state-of-the-art methodologies to identify biomarkers (inflammatory, angiogenesis, vascular injury, metabolic, and neurodegenerative markers, transcriptional profiling of individual cells, and telomere length) of early-onset functional deficits including both physical and mental health. Specifically, within the context of the negative effects of social adversity and the positive influences of social resources and coping skills, we will evaluate: Aim 1. the role of immune and endocrine dysregulation in physical and mental health outcomes in adults with FASD\/PAE; Aim 2 the impact of PAE and the possible role of PAE-induced immune and endocrine dysregulation on neurocognitive performance and markers of early-onset functional deficits in adults with FASD\/PAE in comparison to age-matched controls and healthy older individuals.<\/p>\n In addition to physical, neurocognitive, physiological and behavioral abnormalities\/deficits that occur following prenatal alcohol exposure (PAE), our findings in CIFASD 4 suggest negative impacts on both physical and mental health outcomes in midlife, with many health problems occurring earlier than would be expected in the general population. Findings also indicate that PAE is associated with long-lasting, adverse changes in immune and endocrine function, starting in infancy and lasting into adulthood. Using a \u201cwhole body, whole lifespan\u201d approach, we will investigate how PAE-induced alterations in the immune and endocrine systems may be key drivers of early-onset health and functional deficits in adults with FASD.<\/p>\n Designing a Hybrid Intervention Strategy to Reduce Alcohol Exposed Pregnancies<\/strong> U01 AA030187<\/span> | New York University<\/p>\n Prenatal alcohol exposure (PAE) increases the risk for Fetal Alcohol Spectrum Disorders, adversely affecting physical, cognitive, motor, and neurodevelopmental delay. In a pilot study (N=318) conducted by our U.S.-Rusian team at the Irkutsk Regional Maternity Hospital (RMH), 59% of women tested positive for alcohol consumption as assessed by a laboratory-confirmed alcohol biomarker (PEth). The proposed study will adapt an effective alcohol reduction intervention evaluated in Russia among non-pregnant alcohol-using women to optimize its efficacy for alcohol-using women in prenatal care. We propose to implement a randomized controlled trial (N=720) to assess the efficacy of the alcohol reduction intervention, relative to standard-of-care, in (1) reducing alcohol consumption among pregnant women in prenatal care, 2) reducing poor birth outcomes, and 3) reducing infants\u2019 alcohol-related physical and facial characteristics, and cognitive, motor and neurodevelopmental outcomes. We will recruit women at their first prenatal visit to the Irkutsk RMH. Eligible women (1) are >18 years; (2) provide informed consent; (3) have a positive rapid point-of-care urine test for recent alcohol use; and (4) \u22648 weeks gestation complete a baseline assessment. Women are randomized to one of two conditions: the intervention condition, which includes standard-of-care plus the alcohol reduction intervention, or the comparison condition, which provides standard-of-care only. In the alcohol reduction intervention, participants receive: (1) a computer-delivered component to enhance knowledge, norms, and motivation for alcohol reduction, and (2) a brief obstetrician-delivered component reinforcing the computer-delivered content. The alcohol reduction intervention is theory-driven and uses motivational enhancement strategies to promote alcohol reduction. The alcohol reduction intervention is delivered to women on three occasions, following their baseline, 2nd-trimester, and 3rd-trimester assessments. Women in the comparison condition complete assessments on the same schedule. To assess infant birth outcomes, we will abstract medical records shortly after delivery. To assess physical and facial characteristics and cognitive, motor, and neurodevelopmental outcomes, all mothers return with their infants to complete 6- and 12-month infant assessments. An intent-to-treat analysis evaluates the efficacy of the intervention condition relative to the comparison condition in enhancing the proportion of women detected with a laboratory-confirmed negative PEth test. Other analyses assess intervention effects on birth outcomes, infant physical and facial characteristics, and cognitive, motor, and developmental outcomes at 6- and 12-months. The proposed research is scientifically and clinically significant. If demonstrated effective, the intervention may represent a scalable alcohol reduction strategy for prenatal care in other maternity hospitals in Russia and elsewhere to reduce prenatal alcohol exposure and alcohol-related birth and infant developmental outcomes. If successful, this would be the first prevention intervention conducted as part of CIFASD.<\/p>\n This study develops, implements, and rigorously tests the effectiveness of an intervention administered in prenatal care to reduce women\u2019s alcohol consumption during pregnancy, reduce alcohol-related birth outcomes, and reduce the proportion of infants observed with physical, cognitive, motor, and neurodevelopmental deficits at 6- and 12-month follow-up<\/p>\n Assessment of Fetal Alcohol Spectrum Disorders (FASD) Using Novel Web-Based Tools<\/strong> U01 AA014834<\/span> | San Diego State University<\/p>\n The detrimental effects of prenatal alcohol exposure, including cognitive, behavioral, and physical impacts, have been well documented over several decades. They include long-standing effects on multiple domains of function. Alcohol-affected individuals often go unrecognized. In addition, wait times for evaluation can be quite long, further delaying the accurate identification of affected individuals. Effective online screening tools can decrease wait times and streamline evaluations in specialty clinics. Prenatal alcohol exposure continues to represent a significant public health concern and increased efforts at documenting risk, improving identification, and providing clinically-efficient tools are paramount. As such, the overarching aim of this proposal is to improve the screening for prenatal alcohol exposure and fetal alcohol spectrum disorder (FASD) by deploying web-based tools that aid in clinical evaluation. Two main tools will be used, the FASD-Tree and the Brief Assessment of Individual Neurobehavior \u2013 online version (BRAIN-online). Both tools use web-based technology for collecting data and provide the clinician with information about the individual\u2019s physical, behavioral, and cognitive attributes. Specifically, the FASD-Tree records physical and behavioral data, and BRAIN-online measures impulsivity, attention, problem-solving, processing speed, memory, spatial working memory, and set-shifting. To achieve the aims of this study, child subjects (6-17y) will be evaluated using either the combination of FASD-Tree and BRAIN-online or BRAIN-online alone (Aim 1-3). Parents will complete online questionnaires regarding their child\u2019s background, demographics, and behavior and some children will be given a standardized in-person neuropsychological test battery. In Aim 1, we will examine the relation between FASD-Tree and BRAIN-online, including classification accuracy, sensitivity, and specificity for each tool and their combination. In Aim 2, data from these novel tools will be combined with traditional and advanced (e.g., MorpheusQ and 3D facial imaging) physical measurements collected through other CIFASD projects. The combination of measures used in the proposed research will result in a convenient, scalable, and cost-effective adjunct to standard diagnostic tools.<\/p>\n This project is directly relevant to public health concerns related to the effects of prenatal alcohol exposure on child health and development. This study aims to improve the screening of FASD by deploying web-based tools that aid in clinical evaluation. Two main tools will be used, the FASD-Tree and the Brief Assessment of Individual Neurobehavior \u2013 online version (BRAIN-online). Both tools use web-based technology for collecting data and provide the clinician with information about the individual\u2019s physical, behavioral, and cognitive attributes. Data from these novel tools will be combined with traditional and advanced physical measurements collected through other CIFASD projects and will enhance clinical decision-making.<\/p>\n Leveraging Technology to Increase Quality of Life for FASD across the Lifespan<\/strong> U01 AA026104<\/span> | University of Rochester<\/p>\n People with fetal alcohol spectrum disorders (FASD) experience barriers to care and a lower quality of life (QOL). Responsive to the Collaborative Initiative on FASD (CIFASD5) objectives of improving interventions and early case identification, this proposal evaluates three developmentally-appropriate and scalable interventions to improve QOL across the lifespan. Each intervention leverages technology to increase accessibility and overcome significant barriers to care. These technological interventions are versatile with good potential for dissemination, offering high potential public health impact. All three interventions are theoretically grounded in self-determination theory (SDT) and are integrated with useful best practices in \u201cFASD-Informed Care,\u201d derived from FASD research, clinical wisdom, and policy. Our methodological approach builds on our success developing mobile health (mHealth) applications within CIFASD4, which has included the Families Moving Forward (FMF) Connect app for caregivers of children ages 3-12 (U01 AA026104) and the My Health Coach app for adults with FASD (UH2 AA02050). Study aims will be accomplished using our established systematic user-centered design approach to mHealth interventions, which emphasizes engagement of key stakeholders throughout the development and testing process. Trial design and outcome measurement are guided by implementation science frameworks with the vision towards optimizing success of future dissemination in community settings. Aim 1 tests whether the \u201cProvider-Assisted FMF Connect\u201d intervention and an Extension of Community Healthcare Outcomes (ECHO) implementation package increases mental health providers\u2019 (n=250) FASD-informed care knowledge, self- efficacy, and practice change (including screening and diagnosis of FASD). We hypothesize mental health providers trained in Provider-Assisted FMF Connect through ECHO tele-mentoring will evidence greater practice change compared to providers in self-directed implementation or waitlist conditions. A larger-scale efficacy trial, Aim 2 will test whether the My Health Coach app improves SDT and QOL outcomes for adults with FASD (n=120). Patterns of app usage relating to outcomes will guide further app refinements and dissemination. Leveraging advisory board and focus group input, Aim 3 will develop and assess usability of a caregiver-assisted mHealth app for adolescents called the \u201cDetermined\u201d app system. The Determined app system will include both adolescent and caregiver apps, with synchronized features supporting adolescent self-determination skill building, caregiver autonomy-supportive parenting, and family QOL. Inclusion of these three aims across the lifespan facilitates efficient and mutually informative intervention development. It also addresses gaps in intervention research, especially in adolescence and adulthood. All three aims draw from diverse geographic regions, benefitting directly from recruitment via other CIFASD sites yet expanding beyond them. To other CIFASD5 projects and investigators, we provide much needed, scalable interventions to offer their participants and a clinical setting to test new diagnostic innovations. From findings of our CIFASD colleagues, we will glean content vital to improve our interventions.<\/p>\n Most people with fetal alcohol spectrum disorders (FASD) cannot access FASD-informed interventions and experience lower quality of life. This project will develop and evaluate three developmentally-appropriate FASD-informed interventions targeting quality of life at a different life phase. Each intervention leverages technology to increase accessibility and overcome significant barriers to care.<\/p>\n Defining translational approaches for the image-based detection of prenatal alcohol exposure<\/strong> U01 AA014809<\/span> | University of Oxford<\/p>\n<\/a> This project brings experts together to better understand how prenatal alcohol affects the developing baby, so that we can better treat and prevent fetal alcohol spectrum disorders (FASD). Our goals are to better identify individuals who have been exposed to alcohol prenatally, to determine factors that increase or reduce risk to FASD, to understand the effects of prenatal alcohol exposure across the lifespan, and to develop treatments for FASD. We are investigating new mobile eHealth approaches to better achieve these goals, providing scalable tools that can be used to help identify and treat individuals with FASD, even in remote locations.<\/p>\n
<\/a>FASD Diagnostic Telemedicine Resource<\/h2>\n
PI: Miguel del Campo<\/a><\/h5>\n
<\/a> Effective screening and diagnoses of fetal alcohol spectrum disorders (FASD) is challenging, limiting our ability to target prevention and intervention strategies. This core resource first ensures that the physical components of FASD are identified accurately and consistently in all CIFASD projects involving human subjects. With the goal of improving precision and increasing access to screening and diagnosis, we will use standardized procedures to train all examiners involved in these projects and will closely supervise their performance. We will also determine of new automated tools can accurately identify physical features associated with prenatal alcohol exposure, in an effort to increase accessibility and accuracy of diagnoses. Finally, we will test a novel system for screening of FASD in Alaska, with the goal of providing a screening system for remote underserved areas.<\/p>\n
<\/a>
<\/a><\/div>\n
<\/a>CIFASD Data Coordination Resource<\/h2>\n
PI: Leah Wetherill<\/a><\/h5>\n
<\/a> The most significant contributions to understanding health-related issues have resulted from scientists sharing their data and working together. Fully understanding the impact of prenatal alcohol exposure (PAE), requires the same type of collaboration. CIFASD investigators study how PAE affects the brain, behavior, immune system, physical health, and physical features. They are also trying to identify markers that could indicate conditions associated with PAE, and to find ways to help individuals and families cope with the effects from PAE. Each investigator uploads their data to the Data Coordination Resource, where we harmonize and store it in a safe, central online location for CIFASD investigators. We also transfer the data to the National Institute on Alcohol Abuse and Alcoholism Data Archive, where approved researchers can explore relationships in this wealth of data. Our team is dedicated to providing safe and easy access to this invaluable data, to better understand the effects of PAE throughout a person\u2019s life.<\/p>\n
<\/a>
<\/a><\/div>\n
<\/a>Cardiovascular Disease in Fetal Alcohol Spectrum Disorder<\/h2>\n
MPIs: Caroline Burns<\/a> and Geoff Burns<\/a><\/h5>\n
<\/a>
<\/a> Early stages of heart formation occur within the first weeks of fetal development, making the heart vulnerable to damage caused by alcohol exposure early in pregnancy. Many patients with FASD are born with visible heart problems called congenital heart defects. However, those born without visible heart problems may still have hidden issues with their hearts that will become a problem later in life. Importantly, there is a poor understanding of cardiovascular health outcomes in adult patients with FASD. We will investigate the incidence of cardiovascular diseases in patients with FASD across the life span. Results from these studies will help us know whether being exposed to alcohol before birth is a risk factor for adult heart problems and whether early intervention could help. We will also use a zebrafish model of prenatal alcohol exposure to determine the impacts of alcohol exposure on heart structure, function, and gene expression.<\/p>\n
<\/a><\/div>\n
<\/a>Whole body Effects of PAE across the Life Span: Early Markers of & Clinical Interventions for Children and Adolescents in Ukraine<\/h2>\n
PI: Christina Chambers<\/a><\/h5>\n
<\/a> Emerging data suggest that adults with fetal alcohol spectrum disorders (FASD) have a wide range of co-occurring health challenges, including cardiovascular, metabolic, and mental health issues that may affect quality and length of life. This project will evaluate about 300 children and adolescents who have previously been followed for prenatal alcohol exposure in the U.S. and in Ukraine. The study will look for early clinical signs and biomarkers for these co-occurring health conditions. This work is essential to better understand how often and how early in the child\u2019s life these health conditions are likely to occur. Findings can lead to recommendations for clinical assessments, as well as early interventions in children or adolescents with FASD to help prevent progression of disease. These results may improve overall health across the lifespan.<\/p>\n
<\/a>A Multisite Study of Prenatal Alcohol Exposure: Effects of Inflammation and Endocrine Dysfunction in Adulthood<\/h2>\n
MPIs: Claire Coles<\/a> and Joanne Weinberg<\/a><\/h5>\n
<\/a>
<\/a> A lot is known about the effects of prenatal alcohol exposure (PAE) in children, but little is known about the long-term effects of PAE as individuals grow into adulthood. Our previous studies found that PAE negatively affects both physical and mental health in midlife, with many health problems occurring earlier than compared to the general population. Working at three North American sites, we are extending this research to examine how PAE impacts not only health, but also cognitive and adaptive function, as people age. We are also investigating how early life adversity, and lack of social resources and coping skills, may modify or increase the effects of PAE. Finally, we are investigating whether changes in key biological systems known to be affected by PAE may play a role in the increased risk for negative outcomes, pointing the way to possible novel intervention strategies to improve quality of life for this vulnerable population.<\/p>\n
<\/a><\/div>\n
<\/a>Designing a Hybrid Intervention Strategy to Reduce Alcohol Exposed Pregnancies<\/h2>\n
PI: Ralph DiClemente<\/a><\/h5>\n
<\/a> This project is designed to reduce alcohol use among women in prenatal care as one strategy for preventing FASD. Women are recruited at clinics during routine visits for prenatal care. Women who agree to participate and are identified as using alcohol complete a computerized assessment that measures alcohol use, and other risk factors. Women also provide a small blood sample to assess alcohol use. After completing these assessments, women are assigned, by chance alone, to receive the usual care from their Obstetrician, or to receive usual care from their Obstetrician plus a brief motivational counseling intervention that includes nurse-delivered and computer-delivered motivational counseling. We will monitor alcohol use during prenatal care and assess birth outcomes at delivery. Women participating in the motivational counseling intervention are expected to reduce their alcohol use and have fewer poor birth outcomes.<\/p>\n
<\/a>Assessment of Fetal Alcohol Spectrum Disorders (FASD) Using Novel Web-Based Tools<\/h2>\n
PI: Sarah Mattson<\/a><\/h5>\n
<\/a> Our project is aimed at using online tools that can aid in the assessment and diagnosis of individuals with FASD. The two main tools used are the FASD-Tree, a screening tool for FASD, and the Brief Assessment of Individual Neurobehavior – online version (BRAIN-online), which assesses cognitive performance. Together, these tools will allow individual clinicians to assess patients for FASD in an efficient and cost-effective way. As part of the project, individuals who are being assessed for FASD will be examined using a physical exam, parent\/caregiver questionnaires, and BRAIN-online. Results will be given to the clinician who will provide feedback to the individual and their family. In addition, patients will be assessed with measures from other CIFASD projects, including 3D facial imaging and other apps to detect facial features. Data from these projects will be combined with the ultimate goal of making diagnosis of FASD easier and cheaper to accomplish, especially in remote or less-resourced settings.<\/p>\n
<\/a>
<\/a><\/div>\n
<\/a>Leveraging Technology to Increase Quality of Life for FASD across the Lifespan<\/h2>\n
MPIs: Christie L. M. Petrenko<\/a> and Cristiano Tapparello<\/a><\/h5>\n
<\/a>
<\/a> Our goal is to improve quality of life for people with FASD across the lifespan. This project will test the effectiveness of phone and web applications to provide support at three different developmental periods. For children, we will train mental health providers to use our previously developed Families Moving Forward Connect app, using different methods to determine which is most effective. This app helps children and their families better cope with challenges faced. We are also developing apps for adolescents with FASD and their parents to support communication and skill building. Finally, we will test the My Health Coach app to help adults with FASD manage their health and daily life activities. These apps provide potential interventions that are highly accessible.<\/p>\n
<\/a>
<\/a><\/div>\n
<\/a>Defining Translational Approaches for the Image-Based Detection of Prenatal Alcohol Exposure<\/h2>\n
PI: Michael Suttie<\/a><\/h5>\n